In-House vs Outsourced Drug Testing
Testing in house looks cheaper on a spreadsheet, because the comparison is usually a device price against a service price. The real comparison includes staff time, training, confirmation testing, and what happens when the person running it leaves.
What Each Approach Actually Covers
In house generally means your own staff collect specimens on site using instant screening devices, and your own staff document the result. Non-negative results still have to go somewhere for confirmation.
Outsourced means collections, laboratory confirmation, Medical Review Officer review, reporting, and recordkeeping are handled by a provider, with your team ordering tests and receiving verified results.
The two are not mutually exclusive, and the sensible answer for many employers is a mix.
Want the comparison run against your numbers?Five questions, about a minute. A specialist follows up within one business day.
Request a SpecialistThe Costs Nobody Puts on a Quote
An in-house comparison that only counts device price is missing most of the program:
- Staff time per test. Collection, observation, documentation, and filing, multiplied by your test volume.
- Training, and retraining. Collectors need to know the procedure, chain of custody, and how to handle refusals or unusual specimens, and turnover means doing it again.
- Inventory management. Devices expire. Someone tracks stock across every site and replaces what ages out.
- Confirmation testing. Non-negative results still need a laboratory and an MRO, so that cost does not disappear, it just applies to fewer tests.
- Records. Retention, retrieval, and confidentiality, at every location that tests.
- Program continuity. When the person who ran it leaves, in-house programs stall more often than outsourced ones.
Where In-House Genuinely Makes Sense
- A single site with on-site clinical or safety staff who already handle related duties.
- High volume at one location, where per-test savings are real and the work is concentrated.
- Situations where speed matters more than anything, such as immediate post-incident screening, with confirmation sent out.
- Where someone's job description already includes running the program, with time allocated for it.
Where It Usually Does Not
- Multiple sites, because you are now training and supplying collectors everywhere and consistency degrades.
- Random testing programs, where independence in selection matters and doing it internally invites the accusation that it was not truly random.
- Reasonable suspicion testing, where an independent collection is worth more than the money saved.
- Distributed or remote workforces, where there is nobody on site to collect anything.
The one rule either way: never act on an unconfirmed non-negative screen. Laboratory confirmation and Medical Review Officer review exist to protect employees with legitimate prescriptions and to protect you from acting on a result that would not survive scrutiny. It is the step most worth paying for.
The Hybrid Most Employers Land On
Instant screening on site where speed matters, confirmation and MRO review handled outside, and an outside program running random selection, follow-up schedules, and records. You keep the responsiveness, and the parts that require independence and continuity sit with someone whose job they are.
If you are weighing this, choose In-house supplies on the form and say what you run today. A specialist will price both paths against your actual volume rather than telling you which one to pick.
Common questions
Is testing in house actually cheaper?
Per test, often yes, because you are buying devices rather than a service. Per program, frequently no, once you count staff time for collection and documentation, training, storage and expiry management, confirmation testing for non-negative results, and the administrative work of pools and records. The honest answer depends on volume, how many sites you have, and whether someone's job already includes this work.
What can an instant test actually tell us?
An initial screening result. A negative can be treated as negative. A non-negative is not a positive and should not be acted on as one: it needs laboratory confirmation and Medical Review Officer review before any employment decision. Employers who skip that step because the device showed a line are taking the single largest risk in this entire subject.
Who can collect a specimen in house?
Whoever your policy designates, but they need training in the collection procedure, chain of custody, and how to handle a refusal or an unusual specimen, and that training should be documented. The person's independence matters too: a supervisor collecting from their own direct report is a fact you would rather not be explaining later.
Can we do both?
Yes, and it is a common structure. Some employers run instant screening on site for speed, then send non-negatives out for confirmation and MRO review, while an outside program handles random selection, records, and the testing reasons that need independence. Tell us on the form if that is what you are considering.
What usually goes wrong with in-house programs?
Four things, in order: acting on an unconfirmed screen, expired devices, documentation that does not survive scrutiny, and the program quietly stopping when the person who ran it leaves. None are inevitable, but all four are common enough to plan against.
Compare Both Against Your Numbers
Request a testing specialist
Answer five quick questions. There is no cost and no obligation.
Sources and review
This page is general information about employer drug testing, not legal advice. Drug testing rules differ by state and by industry. Check with your own counsel before setting or changing a testing policy.